Drugs / SELA-070
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03148925 | May 2017 → Oct 2018 | — | Selecta Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SELA-070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03148925 ↗ |
| Modality | Vaccine | “SELA-070 Nicotine Vaccine” NCT03148925 ↗ |
| Route | Subcutaneous | “Increasing subcutaneous doses of SELA-070 will be administered” NCT03148925 ↗ |